The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2023 | Assessing metabolic tumor volume as a prognostic marker before CAR-T therapy for DLBCL
Michael Bishop, MD, University of Chicago, Chicago, IL, discusses the use of metabolic tumor volume (MTV) as a prognostic marker prior to CAR-T therapy, and how it should be assessed in patients undergoing treatment for diffuse large B-cell lymphoma (DLBCL). This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Membership on a Advisory Board or Consultant: KITE/Gilead, Novartis, CRISPR Therapeutics, Autolus Therapeutics, BMS/JUNO Therapeutics, Incyte, Sana Biotechnology, Iovance Biotherapeutics, In8bio, Chimeric Therapeutics
Speakers Bureau: BMS, Kite/Gilead, Servier, AstraZeneca, ADC Therapeutics, Incyte
